MedTrace Logo

Empagliflozin and Atrial Fibrillation Treatment

NCT04583813 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 400

Last updated 2021-04-02

No results posted yet for this study

Summary

The primary purpose of this trial is to evaluate the impact of empagliflozin, as compared with placebo, in patients with diabetes mellitus or overweight, heart failure and atrial fibrillation.

Conditions

Interventions

DRUG

Empagliflozin

Empagliflozin 10 mg oral tablet, once daily, for 24 months

OTHER

Placebo

Empagliflozin matching placebo, once daily, for 24 months

Sponsors & Collaborators

  • Miulli General Hospital

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-09-30
Primary Completion
2024-01-31
Completion
2024-04-30

Countries

  • Italy

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04583813 on ClinicalTrials.gov